Universal Beteiligungs und Servicegesellschaft mbH Raises Holdings in ResMed Inc. (NYSE:RMD)

Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 12.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 95,874 shares of the medical equipment provider's stock after buying an additional 10,431 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.07% of ResMed worth $21,461,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RMD. Geode Capital Management LLC boosted its position in shares of ResMed by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider's stock valued at $899,860,000 after acquiring an additional 85,270 shares during the last quarter. Invesco Ltd. increased its holdings in shares of ResMed by 32.2% during the 4th quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock worth $531,706,000 after buying an additional 566,046 shares during the last quarter. Northern Trust Corp increased its holdings in shares of ResMed by 20.6% during the 4th quarter. Northern Trust Corp now owns 1,702,590 shares of the medical equipment provider's stock worth $389,365,000 after buying an additional 290,664 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of ResMed by 28.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 954,612 shares of the medical equipment provider's stock valued at $218,310,000 after buying an additional 212,201 shares during the period. Finally, Los Angeles Capital Management LLC lifted its holdings in ResMed by 15.6% in the first quarter. Los Angeles Capital Management LLC now owns 773,159 shares of the medical equipment provider's stock valued at $173,072,000 after acquiring an additional 104,251 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

ResMed Stock Up 0.7%

NYSE RMD traded up $1.79 during trading hours on Friday, hitting $275.29. 1,063,916 shares of the company were exchanged, compared to its average volume of 824,604. The company has a 50 day moving average of $253.70 and a two-hundred day moving average of $238.86. The company has a quick ratio of 2.49, a current ratio of 3.41 and a debt-to-equity ratio of 0.12. The firm has a market cap of $40.36 billion, a price-to-earnings ratio of 30.90, a PEG ratio of 1.71 and a beta of 0.77. ResMed Inc. has a 52-week low of $196.43 and a 52-week high of $275.80.

ResMed (NYSE:RMD - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.01. ResMed had a net margin of 26.15% and a return on equity of 25.67%. The firm had revenue of $1.29 billion for the quarter, compared to analysts' expectations of $1.28 billion. During the same quarter last year, the company earned $2.13 earnings per share. The firm's revenue was up 7.9% compared to the same quarter last year. Equities research analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on RMD. JPMorgan Chase & Co. lifted their target price on ResMed from $286.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, April 24th. Royal Bank Of Canada raised shares of ResMed from a "sector perform" rating to an "outperform" rating and increased their target price for the stock from $255.00 to $294.00 in a research note on Tuesday, July 15th. Mizuho boosted their price target on shares of ResMed from $250.00 to $270.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Morgan Stanley set a $286.00 price objective on shares of ResMed and gave the stock an "overweight" rating in a report on Tuesday, May 20th. Finally, KeyCorp set a $274.00 target price on shares of ResMed in a report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, ResMed currently has an average rating of "Moderate Buy" and an average price target of $263.00.

Insider Transactions at ResMed

In other news, CEO Michael J. Farrell sold 8,009 shares of the company's stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $256.72, for a total transaction of $2,056,070.48. Following the completion of the transaction, the chief executive officer directly owned 455,503 shares of the company's stock, valued at approximately $116,936,730.16. This represents a 1.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Witte Jan De sold 2,000 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $243.47, for a total value of $486,940.00. Following the completion of the transaction, the director owned 5,806 shares in the company, valued at approximately $1,413,586.82. The trade was a 25.62% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 29,013 shares of company stock valued at $7,238,913. Insiders own 0.71% of the company's stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.